RCM
BIOTU

Rivernorth Capital Management’s Biotech Acquisition Company Unit BIOTU Stock Holding History

Rivernorth Capital Management’s Portfolio BIOTU Stock Details BIOTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-218,102
Closed -$2.2M – 646
2021
Q2 		$2.2M Buy
218,102
+193,102
+772% +$1.93M 0.13% 122
2021
Q1 		$247K Buy
+25,000
New +$257K 0.01% 317

Other funds holding BIOTU

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.76% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
CCFM
Cohen & Co Financial Management New York $18.3M AUM 73.48% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Rivernorth Capital Management's BIOTU Position: Q3 2021 in Review

Rivernorth Capital Management sold out of Biotech Acquisition Company Unit (BIOTU) in Q3 2021, closing a stake of 218,102 shares — an estimated $2.2M sold.

Rivernorth Capital Management first reported a position in BIOTU in Q1 2021 and held it in 2 quarters. The position peaked at $2.2M in Q2 2021. 34 funds tracked by Wall St. Rank hold BIOTU as of Q3 2021.

  • Rivernorth Capital Management reported no remaining Biotech Acquisition Company Unit position as of Q3 2021 after selling out during the quarter.
  • Rivernorth Capital Management sold 218,102 Biotech Acquisition Company Unit shares in Q3 2021, an estimated $2.2M.
  • Rivernorth Capital Management first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 2 quarters.
  • Rivernorth Capital Management's Biotech Acquisition Company Unit position peaked at $2.2M in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q3 2021.

Based on Rivernorth Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.